Last reviewed · How we verify

3TC — Competitive Intelligence Brief

3TC (3TC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside reverse transcriptase inhibitor (NRTI). Area: Infectious Disease.

marketed Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase; hepatitis B polymerase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

3TC (3TC) — Avexa. 3TC (lamivudine) is a nucleoside reverse transcriptase inhibitor that blocks HIV reverse transcriptase, preventing viral replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
3TC TARGET 3TC Avexa marketed Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase; hepatitis B polymerase
Tenofovir (TDF) Tenofovir (TDF) French National Agency for Research on AIDS and Viral Hepatitis marketed Nucleotide reverse transcriptase inhibitor (NtRTI) HIV reverse transcriptase; Hepatitis B polymerase
Abacavir/Lamivudine Abacavir/Lamivudine GlaxoSmithKline marketed Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase
Zidovudine (drug) Zidovudine (drug) Johann Wolfgang Goethe University Hospital marketed Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase
Twice-daily ABC+3TC Twice-daily ABC+3TC Medical Research Council marketed Nucleoside reverse transcriptase inhibitor (NRTI) combination HIV reverse transcriptase
AZT AZT Johns Hopkins Bloomberg School of Public Health marketed Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase
Telbivudine treatment Telbivudine treatment Southeast University, China marketed Nucleoside reverse transcriptase inhibitor (NRTI) Hepatitis B virus reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside reverse transcriptase inhibitor (NRTI) class)

  1. French National Agency for Research on AIDS and Viral Hepatitis · 3 drugs in this class
  2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
  3. ViiV Healthcare · 2 drugs in this class
  4. Nanfang Hospital, Southern Medical University · 2 drugs in this class
  5. Asan Medical Center · 1 drug in this class
  6. Dong-A ST Co., Ltd. · 1 drug in this class
  7. Bristol-Myers Squibb · 1 drug in this class
  8. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
  9. Fu-Sheng Wang · 1 drug in this class
  10. Avexa · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 3TC — Competitive Intelligence Brief. https://druglandscape.com/ci/3tc. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: